Rev-erb agonist improves adverse cardiac remodeling and survival in myocardial infarction through an anti-inflammatory mechanism
Endin Nokik Stujanna(University of Tsukuba), Kazutaka Aonuma(Mito Saiseikai General Hospital)
Cited by 100
Related Papers
Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
|Kidney International|2019|435
The APHRS's 2013 statement on antithrombotic therapy of patients with nonvalvular atrial fibrillation
|Journal of Arrhythmia|2013|82